Durvalumab: A Review in Extensive-Stage SCLC
Funding The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest Zaina T. Al-Salama is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability not applicable
Additional information about this Adis Drug Review can be found here
Durvalumab (IMFINZI®), a fully human monoclonal antibody against programmed cell death-ligand 1 (PD-L1), is approved
for use in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). In the pivotal phase III CASPIAN trial in previously untreated adults with
ES-SCLC, the addition of durvalumab to chemotherapy for up to 4 cycles followed by maintenance durvalumab was associated with a significantly longer overall survival and a favourable hazard ratio for progression-free survival compared with
chemotherapy alone for up to 6 cycles. A higher proportion of patients in the durvalumab plus chemotherapy group had an
objective response compared with the chemotherapy alone group. The efficacy of durvalumab was also sustained with longer
follow-up. Durvalumab in combination with etoposide and either carboplatin or cisplatin had a manageable tolerability profile
in patients with ES-SCLC. Given the available evidence, durvalumab in combination with etoposide and either carboplatin
or cisplatin represents a valuable treatment option for the first-line treatment of patients with ES-SCLC, and is an accepted
standard of care option in this setting.
© Springer Nature Switzerland AG 2021